The clinical benefit of PD-1 inhibitors for patients with PTCLs is also being investigated in several clinical trials, with an ORR of approximately 33–40% for patients with relapsed or refractory PTCL (18, 19). This evidence concerns the gene PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma.